13 June 2018
Notice of results for the year ended 31 March 2018
Analyst and investor briefing
Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it will issue its audited full year results for the year ended 31 March 2018 on Tuesday, 10 July 2018.
An analyst briefing will take place at the offices of Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Tuesday, 10 July 2018.
Collagen Solutions will also be hosting an afternoon presentation for investors on Tuesday 10 July 2018, where Jamal Rushdy, CEO of the Company, will summarise the full year results and:
- provide insight into the underlying business trends;
- an overview of the ongoing positioning of the Company; and
- outline the key milestones expected over the next period.
Hilary Spence, CFO, will present key financial highlights, outlook and insight from her first few months with Collagen Solutions.
This investor event will take place at the Copper Bar, upstairs at Balls Brothers, 6 Adams Court, Old Broad St, London, EC2N 1DX at 4.30pm for a 4.45pm start. This will be followed by drinks and canapes, and a chance to network. A video of the presentation will be available on the Company's website shortly afterwards: http://ir.collagensolutions.com/content/investors/presentations.asp.
If you would like to register to attend the analyst or investor briefing or require further information, please contact Walbrook PR on 020 7933 8780 or email firstname.lastname@example.org.
|Collagen Solutions Plc
Jamal Rushdy, CEO
Hilary Spence, CFO
|Lisa Baderoon, Head of Investor Relations||Tel: +44 (0) 7721 413 496 or email@example.com|
|Cenkos Securities plc (Nominated Adviser and Broker)
Steve Cox (Corporate Finance)
|Tel: 0207 397 8900|
|Walbrook PR Ltd||Tel: 020 7933 8780 or firstname.lastname@example.org|
|Anna Dunphy||Mob: 07876 741 001|
|Helen Cresswell||Mob: 07841 917 679|
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com.